BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16282721)

  • 1. [Pharmacogenomic data for personalized medicines].
    Yamazaki H
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1886-90. PubMed ID: 16282721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic applications in oncology.
    Walko CM; Ikediobi O
    J Pharm Pract; 2012 Aug; 25(4):439-46. PubMed ID: 22907843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
    Lee SY; McLeod HL
    J Pathol; 2011 Jan; 223(1):15-27. PubMed ID: 20818641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of cytotoxic drugs.
    Daly AK; Hall AG
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):301-8. PubMed ID: 12113035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
    Deeken JF; Figg WD; Bates SE; Sparreboom A
    Anticancer Drugs; 2007 Feb; 18(2):111-26. PubMed ID: 17159598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized drug therapy.
    Daly AK
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):29-36. PubMed ID: 17265738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
    Reynolds KK; McNally BA; Linder MW
    Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
    Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
    Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of breast cancer therapies.
    Hertz DL; McLeod HL; Hoskins JM
    Breast; 2009 Oct; 18 Suppl 3():S59-63. PubMed ID: 19914545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochromes P450 and cancer.
    Kaminsky LS; Spivack SD
    Mol Aspects Med; 1999; 20(1-2):70-84, 137. PubMed ID: 10575653
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.
    Peppercorn J; Hamilton E; Marcom PK; Beskow L; Lyman GH
    Cancer; 2013 Oct; 119(20):3703-9. PubMed ID: 23893861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction.
    ;
    Invest New Drugs; 2005 Dec; 23(6):511. PubMed ID: 16391895
    [No Abstract]   [Full Text] [Related]  

  • 17. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
    Sjöqvist F; Eliasson E
    Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
    Quiñones S L; Rosero P M; Roco A A; Moreno T I; Sasso A J; Varela F N; Cáceres L D; Saavedra S I
    Rev Med Chil; 2008 Oct; 136(10):1327-35. PubMed ID: 19194632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer pharmacogenomics: international trends.
    Yamayoshi Y; Iida E; Tanigawara Y
    Int J Clin Oncol; 2005 Feb; 10(1):5-13. PubMed ID: 15729594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.